On October 27, 2015, the Patent Trial and Appeal Board (PTAB) denied the Coalition for Affordable Drugs' inter partes review (IPR) petition challenging Finnegan client Biogen's patent covering treatments for multiple sclerosis. This is the second IPR petition from the Coalition that the PTAB denied in regard to Biogen's patent. The Board ruled that the Coalition had not shown a reasonable likelihood that it would succeed in a trial at showing the unpatentability of the claims at issue.